Anil Goyal

Anil Goyal

Company: IMMvention Therapeutix

Job title: Chief Executive Officer & Board Director


Panel Discussion: Industry Leader Perspectives on Inflammasome Therapeutic Development & Commercialization 8:30 am

Exploring recent deals in the space: How to raise capital, attract investors and large pharma interest Thinking outside the box when it comes to prioritizing specific disease indications for specific inflammasome therapeutics How to balance commercial considerations of drug development with unmet need across diseases? How crucial is it to demonstrate differentiation from standards of…Read more

day: Day Two

IMM-004 small molecule series that inhibits NLRP3, NLPR1, NLRC4 & AIM2 3:00 pm

Multiple inflammasomes (NLRP3, NLRP1, NLRC4, AIM2) drive many rare and prevalent diseases such as neuroinflammatory, cardiometabolic and rheumatic disease. While drugging only one inflammasome (NLRP3) has been the key focus in the inflammasome space, NLPR3 inhibition alone may not be sufficient to control many diseases where other inflammasomes are activated or cross-activated. Thus, multi-inflammasome inhibition…Read more

day: Day 1 - Track A - Afternoon

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.